Lindbrook Capital LLC Acquires 98 Shares of Humana Inc. (NYSE:HUM)

Lindbrook Capital LLC raised its holdings in shares of Humana Inc. (NYSE:HUM) by 12.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 874 shares of the insurance provider’s stock after acquiring an additional 98 shares during the quarter. Lindbrook Capital LLC’s holdings in Humana were worth $400,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of HUM. abrdn plc increased its holdings in shares of Humana by 123.9% in the fourth quarter. abrdn plc now owns 192,600 shares of the insurance provider’s stock worth $88,174,000 after purchasing an additional 106,586 shares during the last quarter. Vantage Investment Partners LLC increased its holdings in shares of Humana by 46.3% in the fourth quarter. Vantage Investment Partners LLC now owns 15,599 shares of the insurance provider’s stock worth $7,141,000 after purchasing an additional 4,937 shares during the last quarter. HTLF Bank bought a new stake in shares of Humana in the fourth quarter worth about $381,000. Fidelis Capital Partners LLC increased its holdings in shares of Humana by 16.9% in the fourth quarter. Fidelis Capital Partners LLC now owns 1,002 shares of the insurance provider’s stock worth $459,000 after purchasing an additional 145 shares during the last quarter. Finally, Calamos Advisors LLC increased its holdings in shares of Humana by 8.8% in the fourth quarter. Calamos Advisors LLC now owns 76,948 shares of the insurance provider’s stock worth $35,228,000 after purchasing an additional 6,207 shares during the last quarter. 92.38% of the stock is owned by institutional investors.

Humana Stock Performance

Shares of NYSE:HUM opened at $328.33 on Monday. The company has a quick ratio of 1.59, a current ratio of 1.59 and a debt-to-equity ratio of 0.63. The firm has a 50 day moving average of $330.40 and a 200 day moving average of $400.22. Humana Inc. has a 52 week low of $299.23 and a 52 week high of $541.21. The company has a market capitalization of $39.61 billion, a price-to-earnings ratio of 16.57, a price-to-earnings-growth ratio of 1.92 and a beta of 0.45.

Humana (NYSE:HUM) last released its earnings results on Thursday, January 25th. The insurance provider reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.76 by ($0.87). Humana had a net margin of 2.34% and a return on equity of 19.44%. The firm had revenue of $26.46 billion during the quarter, compared to analyst estimates of $25.47 billion. During the same period in the previous year, the company earned $1.62 earnings per share. Humana’s revenue was up 17.9% on a year-over-year basis. On average, sell-side analysts predict that Humana Inc. will post 16.06 earnings per share for the current fiscal year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be given a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.08%. The ex-dividend date is Friday, June 28th. Humana’s payout ratio is 17.86%.

Insider Activity at Humana

In other Humana news, Director Jorge S. Mesquita purchased 545 shares of the stock in a transaction on Tuesday, February 20th. The shares were bought at an average cost of $367.09 per share, with a total value of $200,064.05. Following the completion of the acquisition, the director now owns 2,578 shares in the company, valued at $946,358.02. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 0.29% of the stock is owned by insiders.

Analysts Set New Price Targets

HUM has been the subject of several recent research reports. Cantor Fitzgerald reiterated a “neutral” rating and issued a $391.00 price target on shares of Humana in a research report on Wednesday, April 10th. Deutsche Bank Aktiengesellschaft lowered Humana from a “buy” rating to a “hold” rating and dropped their price target for the stock from $595.00 to $360.00 in a research report on Thursday, January 25th. StockNews.com lowered Humana from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 26th. Wells Fargo & Company dropped their price target on Humana from $413.00 to $350.00 and set an “overweight” rating for the company in a research report on Monday, April 8th. Finally, Argus lowered Humana from a “buy” rating to a “hold” rating in a research report on Wednesday, March 13th. Eleven analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $465.42.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.